Rigontec GmbH

Rigontec GmbH

Kontakt

Am Klopferspitz 19 82152 Planegg
+49 89 200066411

Rigontec is the leader in RIG-I targeting therapeutics. Utilizing our proprietary RIG-I agonist platform, we harness one of the most essential pathways in the innate immune system to pioneer a novel immuno-oncology treatment approach.

Rigontec’s proprietary agonists specifically activate RIG-I, inducing both immediate and long-term anti-tumor immunity and have proven substantial local and systemic tumor regression in several relevant in vivo models.

In addition to malignant diseases, our innovative bifunctional RNA molecules can be developed for the treatment of infectious and inflammatory diseases.

Dieser Eintrag ist nicht vollständig oder enthält inkorrekte Informationen? Bitte gib uns Bescheid: redaktion@munich-startup.de

Um unsere Webseite optimal zu gestalten und fortlaufend verbessern zu können, verwenden wir Cookies. Durch die weitere Nutzung der Webseite stimmst Du der Verwendung von Cookies zu. Weitere Informationen findest Du in unserer Datenschutzerklärung.

The cookie settings on this website are set to "allow cookies" to give you the best browsing experience possible. If you continue to use this website without changing your cookie settings or you click "Accept" below then you are consenting to this.

Close